BIIB019 (Daclizumab)
205MS303
Phase 3 small_molecule terminated
Quick answer
BIIB019 (Daclizumab) for Relapsing-Remitting Multiple Sclerosis is a Phase 3 program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Biogen
- Indication
- Relapsing-Remitting Multiple Sclerosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated